SOURCE: ABV Gold

August 04, 2008 10:39 ET

ABV Gold Inc. Finalizes Acquisition of PharmaCom Biovet LLC

MONTREAL--(Marketwire - August 4, 2008) - Daniel Ryan, President and CEO of ABV Gold Inc. (PINKSHEETS: ABVG), announced today that the essential documents have been signed to drive the acquisition forward with PharmaCom BioVet LLC. The agreement has been signed and it is now in the hands of legal council to have it memorialized, stated Ryan.

Furthermore with the completion of the PharmaCom BioVet LLC acquisition, effective immediately Mr. Daniel Ryan has officially stepped down as President & CEO along with the existing Board Members and has been succeeded by Mr. Gary S. Berthold who has joined ABVG in the capacity of President and Chief Executive Officer.

Mr. Berthold will also be welcoming a management team to ABVG that includes successful leaders from corporate business, companion animal care, pet services industries and renowned medical and academic professionals within the veterinary and oncology fields from around the country. These experts share a commitment towards the growing success and fulfillment of PharmaCom BioVet LLC.

Gary S. Berthold, President & CEO of ABV Gold Inc., states, "We are very pleased to be bringing our company to market. The market for veterinary care for companion animals is growing significantly and is now in excess of a $50 billion dollar industry in the U.S. The procedures and technologies we possess are groundbreaking and state of the art. We expect to be able to take a leadership role in this marketplace in the next 12-24 months. Our margins are such that we expect to deliver great results to company and its shareholders."

About PharmaCom BioVet

PharmaCom BioVet, LLC recognizes the demand as well as the current lack of adequate cancer treatment options or facilities for animal lovers whose pets are suffering from lymphoma and other forms of cancer. Backed by an impressive group of renowned medical specialists in this field, along with a solid business management team, PharmaCom BioVet, LLC is advancing an aggressive business model to establish a network of companion animal cancer treatment centers around the country.

Important Information about Forward-Looking Statements:

All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other events and conditions.

Contact Information